2014
DOI: 10.3747/pdi.2014.00001
|View full text |Cite
|
Sign up to set email alerts
|

Vancomycin: The Tale of the Vanquisher and the Pyrrhic Victory

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
13
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(13 citation statements)
references
References 53 publications
0
13
0
Order By: Relevance
“…Clinically, the target concentration intervention (TCI) has been widely applied and can help maximize clinical benefits [23,24] . For TCI, a proper Pop-PK model is required [25,26] and is valuable in highly variable populations that are receiving a drug with a narrow therapeutic window, eg, vancomycin [27] . TCI focuses on the estimation of the initial dose to achieve the target concentration by calculating the pharmacokinetic (PK) and pharmacodynamic (PD) parameters according to the relevant covariates, such as dosage, treatment duration, and clinical effects during treatment [28] .…”
Section: Introductionmentioning
confidence: 99%
“…Clinically, the target concentration intervention (TCI) has been widely applied and can help maximize clinical benefits [23,24] . For TCI, a proper Pop-PK model is required [25,26] and is valuable in highly variable populations that are receiving a drug with a narrow therapeutic window, eg, vancomycin [27] . TCI focuses on the estimation of the initial dose to achieve the target concentration by calculating the pharmacokinetic (PK) and pharmacodynamic (PD) parameters according to the relevant covariates, such as dosage, treatment duration, and clinical effects during treatment [28] .…”
Section: Introductionmentioning
confidence: 99%
“…MRSA is reported to have distinctive phenotypic and genetic features whether community or hospital acquired (Mammina et al, 2012). Evidence have shown that some strains of S. aureus are found to be resistant to the last line antibiotics (Park and Lui, 2012;De Vriese and Vandecasteele, 2014) and this has restricted the options available for its treatment in many regions of the world (Subedi and Brahmadathan, 2005). One of such regions is Nigeria (Akinyemi et al, 1997) where antibiotic resistance may be due to spontaneous mutation or acquired through plasmid transfer from other resistant bacteria (Bhaktar et al, 2003).…”
mentioning
confidence: 99%
“…There are no reports of this phenomenon with IP vancomycin in adult patients, presumably related to the slow rate of absorption of vancomycin through the peritoneal membrane. In adult PD patients, the bioavailability of IP vancomycin following a 4- to 6-hour exchange is between 30 and 70%, a major factor limiting a rapid rise in plasma levels [9]. …”
Section: Discussionmentioning
confidence: 99%
“…Despite this theoretical concern, relapse rates do not appear to be higher among patients treated with automated PD compared with continuous ambulatory PD [15]. An alternative IP vancomycin dosing strategy has been proposed that involves 25 mg/L of vancomycin in each exchange rather than large doses given every few days [9]. This has the advantage of achieving higher intraperitoneal concentrations and preventing potentially risky systemic levels, though it is certainly more onerous.…”
Section: Discussionmentioning
confidence: 99%